182 related articles for article (PubMed ID: 30551856)
1. Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.
van den Ende T; Smyth E; Hulshof MCCM; van Laarhoven HWM
Best Pract Res Clin Gastroenterol; 2018; 36-37():45-52. PubMed ID: 30551856
[TBL] [Abstract][Full Text] [Related]
2. Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas.
Cox SJ; O'Cathail SM; Coles B; Crosby T; Mukherjee S
Curr Oncol Rep; 2017 Jan; 19(1):7. PubMed ID: 28213876
[TBL] [Abstract][Full Text] [Related]
3. Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers.
Bain GH; Petty RD
Oncologist; 2010; 15(3):270-84. PubMed ID: 20203174
[TBL] [Abstract][Full Text] [Related]
4. Great Debate: Chemoradiation Should be Added to Chemotherapy as a Neoadjuvant Treatment Strategy for Resectable Gastric Adenocarcinoma.
Daniel SK; Badgwell BD; McKinley SK; Strong VE; Poultsides GA
Ann Surg Oncol; 2024 Jan; 31(1):405-412. PubMed ID: 37865940
[TBL] [Abstract][Full Text] [Related]
5. "Harnessing AI for treatment optimization: Neoadjuvant chemotherapy in gastroesophageal cancer".
Sheen AR; Saqib HWU
Eur J Surg Oncol; 2024 Apr; 50(4):108228. PubMed ID: 38430705
[No Abstract] [Full Text] [Related]
6. Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma.
Clements HA; Underwood TJ; Petty RD
Br J Cancer; 2024 Jan; 130(1):9-18. PubMed ID: 37898721
[TBL] [Abstract][Full Text] [Related]
7. Customizing Therapy for Esophageal Cancer: CROSS vs. FLOT.
Tasnim S; Sudarshan M
Ann Surg Oncol; 2024 Jan; 31(1):21-22. PubMed ID: 37833462
[No Abstract] [Full Text] [Related]
8. Comment on "Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from a Japanese Nationwide Study".
Gronnier C
Ann Surg Oncol; 2024 May; 31(5):2815-2817. PubMed ID: 38355781
[No Abstract] [Full Text] [Related]
9. Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma.
Fick CN; Dunne EG; Sihag S; Molena D; Cytryn SL; Janjigian YY; Wu AJ; Worrell SG; Hofstetter WL; Jones DR; Gray KD
Ann Thorac Surg; 2024 Feb; ():. PubMed ID: 38408631
[TBL] [Abstract][Full Text] [Related]
10. Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer.
Li N; Sohal D
Cancer Immunol Immunother; 2023 Dec; 72(12):3939-3952. PubMed ID: 37995002
[TBL] [Abstract][Full Text] [Related]
11. PERFECT trial results: Combining neoadjuvant chemoradiotherapy with atezolizumab is feasible in resectable esophageal adenocarcinoma.
Zhang L
Thorac Cancer; 2021 Jun; 12(12):1797-1799. PubMed ID: 33973394
[No Abstract] [Full Text] [Related]
12. Neoadjuvant treatment for esophageal squamous cell carcinoma.
Baba Y; Watanabe M; Yoshida N; Baba H
World J Gastrointest Oncol; 2014 May; 6(5):121-8. PubMed ID: 24834142
[TBL] [Abstract][Full Text] [Related]
13. Effects of neoadjuvant therapy on health-related quality of life for patients with gastroesophageal cancer.
Holmén A; Jebril W; Ida S; Agustsson T; Lampi M; Rouvelas I; Sunde B; Klevebro F
Eur J Surg Oncol; 2023 Nov; 49(11):107008. PubMed ID: 37673022
[TBL] [Abstract][Full Text] [Related]
14. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy.
Murugaesu N; Wilson GA; Birkbak NJ; Watkins T; McGranahan N; Kumar S; Abbassi-Ghadi N; Salm M; Mitter R; Horswell S; Rowan A; Phillimore B; Biggs J; Begum S; Matthews N; Hochhauser D; Hanna GB; Swanton C
Cancer Discov; 2015 Aug; 5(8):821-831. PubMed ID: 26003801
[TBL] [Abstract][Full Text] [Related]
15. Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy?
Laxague F; Schlottmann F
World J Clin Oncol; 2021 Jul; 12(7):557-564. PubMed ID: 34367928
[TBL] [Abstract][Full Text] [Related]
16. Advances in targeted therapies and new promising targets in esophageal cancer.
Belkhiri A; El-Rifai W
Oncotarget; 2015 Jan; 6(3):1348-58. PubMed ID: 25593196
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal Cancers: Fine-Tuning the Management of Rectal, Esophageal, and Pancreas Cancers.
Olsen JR; Apisarnthanarax S; Murphy JD; Tait D; Huguet F; Hallemeier CL; Jabbour SK
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):1-10. PubMed ID: 31422802
[No Abstract] [Full Text] [Related]
18. Multimodality management of esophageal cancer.
Purwar P; Bambarkar S; Jiwnani S; Karimundackal G; Laskar SG; Pramesh CS
Indian J Surg; 2014 Dec; 76(6):494-503. PubMed ID: 25614726
[TBL] [Abstract][Full Text] [Related]
19. Is neoadjuvant chemotherapy combined with immunotherapy really better than neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma?
Li K; Yang J; Huang Y
J Thorac Cardiovasc Surg; 2024 Mar; ():. PubMed ID: 38551555
[No Abstract] [Full Text] [Related]
20. Improving Outcomes with Chemoradiotherapy in the Mucosal Squamous Cell Carcinomas - Immune Checkpoint Inhibition and Broken Promises.
Samuel R; Samson A; Gilbert DC
Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):764-768. PubMed ID: 37743210
[No Abstract] [Full Text] [Related]
[Next] [New Search]
